Therapeutic Solutions International Inc (TSOI)

[sharky]

The current set of animal experiments demonstrate not only that NanoStilbene™ enhances the ability of the CTLA-4 antibody to reduce tumor size, but also that NanoStilbene™ augments the number of lymphocytes entering the tumor. This data, together with previous publications that pterostilbene itself suppresses a wide variety of tumors, support the possible development of our nutraceutical as an adjuvant to numerous immunotherapies" said Thomas Ichim, Ph.D., Board Member of TSOI and coinventor on the Company's patents.

Numerous independent laboratories have published in the peer reviewed literature that pterostilbene decreases the growth of prostate cancer [3], breast cancer [4], glioma [5], liver cancer [6], esophageal cancer [7], and melanoma [8]. The advantage of NanoStilbene™ as compared to pterostilbene capsules, which are widely available, is that the proprietary nanoformulation allows substantially higher concentrations of pterostilbene to reach the cancer cells.



$TSOI